Unknown

Dataset Information

0

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.


ABSTRACT: To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration.Fifteen patients with unilateral exudative age-related macular degeneration were enrolled. The best-corrected visual acuity was measured and spectral domain optical coherence tomography was performed at baseline and monthly. Full-field electroretinography and multifocal electroretinography were obtained at baseline and 4, 13, and 26 weeks after the first injection. All patients received three monthly intravitreal injections of ziv-aflibercept (1.25 mg) followed by as-needed treatment.Between baseline and 26 weeks, the mean logMAR best-corrected visual acuity improved (P = 0.00408) from 0.93 ± 0.4 (20/200) to 0.82 ± 0.5 (20/160) logarithm of the minimum angle of resolution, respectively; the central retinal thickness decreased significantly (P = 0.0007) from 490.3 ± 155.1 microns to 327.9 ± 101.5 microns; the mean total macular volume decreased significantly (P < 0.0001) from 9.51 ± 1.36 mm to 8.08 ± 1.34 mm, and the a-wave implicit time increased, with no differences in the other full-field electroretinography parameters. The average multifocal electroretinography macular responses within the first central 15° showed significantly (P < 0.05) increased P1 amplitudes at 26 weeks. No systemic or ocular complications developed.Intravitreal ziv-aflibercept significantly improved the best-corrected visual acuity, multifocal electroretinography amplitudes, central retinal thickness, and total macular volume from baseline to 26 weeks. No retinal toxicity on full-field electroretinography or adverse events occurred during the follow-up period.

SUBMITTER: de Oliveira Dias JR 

PROVIDER: S-EPMC5549635 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

CLINICAL AND ELECTROPHYSIOLOGICAL EVALUATION AFTER INTRAVITREAL ZIV-AFLIBERCEPT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.

de Oliveira Dias João Rafael JR   de Andrade Gabriel Costa GC   Kniggendorf Vinicius Ferreira VF   Novais Eduardo Amorim EA   Maia André A   Meyer Carsten C   Watanabe Sung Eun Song SES   Farah Michel Eid ME   Rodrigues Eduardo Büchele EB  

Retina (Philadelphia, Pa.) 20170801 8


<h4>Purpose</h4>To evaluate the 6-month safety and efficacy of ziv-aflibercept intravitreal injections for treating exudative age-related macular degeneration.<h4>Methods</h4>Fifteen patients with unilateral exudative age-related macular degeneration were enrolled. The best-corrected visual acuity was measured and spectral domain optical coherence tomography was performed at baseline and monthly. Full-field electroretinography and multifocal electroretinography were obtained at baseline and 4, 1  ...[more]

Similar Datasets

| S-EPMC6022819 | biostudies-literature
| S-EPMC7885608 | biostudies-literature
| S-EPMC5038569 | biostudies-literature
| S-EPMC5030844 | biostudies-literature
| S-EPMC7961756 | biostudies-literature
| S-EPMC5339812 | biostudies-literature
| S-EPMC7890834 | biostudies-literature
| S-EPMC6958749 | biostudies-literature
| S-EPMC7089719 | biostudies-literature
| S-EPMC4186733 | biostudies-literature